Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 5/20 | 0.32 |
| ▸ | ADCYAP1R1 | P41586 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542186 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2MGAMGAASIMGAM2 | |
| SCHEMBL1543309 | 0.78 | GCGR (0.37) | SMN1; SMN2GAAGCGRADCYAP1R1L3MBTL1 | |
| SCHEMBL3749425 | 0.78 | SYK (0.40) | SMN1; SMN2KCNH2KMT2AL3MBTL1MAPT | |
| SCHEMBL1542332 | 0.77 | L3MBTL1 (0.37) | SMN1; SMN2GAAADCYAP1R1L3MBTL1 | |
| SCHEMBL3762026 | 0.75 | KCNA3 (0.36) | SMN1; SMN2GAAGCGRL3MBTL1 | |
| SCHEMBL3756879 | 0.74 | KCNH2 (0.36) | SMN1; SMN2MGAMGAASIMGAM2 | |
| SCHEMBL3751717 | 0.73 | KCNA3 (0.39) | SMN1; SMN2GAAKMT2AL3MBTL1 | |
| SCHEMBL27833882 | 0.73 | L3MBTL1 (0.36) | SMN1; SMN2GCGRADCYAP1R1L3MBTL1 | |
| SCHEMBL27800943 | 0.70 | SMN1; SMN2 (0.36) | SMN1; SMN2MGAMGAASIMGAM2 | |
| SCHEMBL3754173 | 0.70 | KCNA3 (0.35) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507539-B2 | Potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2013-08-13 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | SMN1; SMN2 3154/4885MGAM 4054/4885GAA 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.